Skip to main content

and
  1. Article

    Open Access

    Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector

    Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effective vaccine against HIV. In this study, an alternative replication-defective flavivirus vector, RepliVax (R...

    M. Giel-Moloney, M. Esteban, B. H. Oakes, M. Vaine, B. Asbach in Scientific Reports (2019)

  2. Article

    Open Access

    Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial

    G Franchini, P Pegu, S Gordon, B Keele, M Doster, Y Guan, G Ferrari, R Pal in Retrovirology (2012)

  3. Article

    Open Access

    Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses

    SL Hulot, BT Korber, G Pantaleo, J Tartaglia, B Jacobs, B Perdiguero in Retrovirology (2012)

  4. Article

    Open Access

    Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2

    L Liao, M Bonsignori, K Hwang, AM Moody, R Park, S Crawford, H Chen in Retrovirology (2012)

  5. No Access

    Article

    Comparison of Monotonic and Cyclic Properties of Ductile Irons in the AFS/DOE Strain-Life Fatigue Database for Cast Iron

    A strain-life fatigue database for cast irons was developed utilizing American Foundry Society (AFS) and the United States Department of Energy (DOE) funding. The database contains monotonic and cyclic propert...

    J. Tartaglia in International Journal of Metalcasting (2012)

  6. Article

    Open Access

    OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines

    B Jacobs, K Kibler, S Wong, T Huynh, S Holechek, K Denzler, W Arndt in Retrovirology (2009)

  7. Article

    Open Access

    OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

    MS de Souza, R Trichavaroj, A Schuetz, W Chuenarom, Y Phuang-ngem in Retrovirology (2009)

  8. No Access

    Article

    Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)

    We tested the canarypox virus vector ALVAC and the genetically attenuated vaccinia virus vector NYVAC as vehicles for achieving local immunomodulation in domestic animals bearing spontaneous tumours. Following...

    T-M Jourdier, C Moste, M-C Bonnet, F Delisle, J-P Tafani, P Devauchelle in Gene Therapy (2003)